A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia

@article{Mu2007AS2,
  title={A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia},
  author={Q. Mu and Kevin Johnson and P. Morgan and E. Grenesko and Christine E. Molnar and B. Anderson and Z. Nahas and F. Kozel and S. Kose and M. Knable and P. Fernandes and D. E. Nichols and R. Mailman and M. George},
  journal={Schizophrenia Research},
  year={2007},
  volume={94},
  pages={332-341}
}
Dopamine D1 receptors play an important role in memory and cognition in non-human primates. Dopamine D1 agonists have been shown to reverse performance deficits in both aged non-human primates and in primates with lesions to dopamine systems. This study explored whether a single dose of the first full D1 agonist dihydrexidine (DAR-0100) would cause changes in brain activity (perfusion) in dopamine-rich brain regions. We used a new gadolinium-contrast magnetic resonance perfusion scanning… Expand
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia
TLDR
A single subcutaneous dose of dihydrexidine is tolerated and safe in patients with schizophrenia and does not produce delayed clinical or neuropsychological improvements. Expand
Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder
TLDR
Findings lend further clinical support to the potential of D1 receptor agonists to treat schizophrenia-spectrum working memory impairments, and suggest a need for further studies with larger group sizes, serum DAR-0100A levels, and a more comprehensive neuropsychological battery. Expand
A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia
TLDR
It is suggested that low doses of D1 agonists that do not result in measureable occupancy of the D1R do not reliably improve cognition in SCZ, unlike the observations in NHP. Expand
Multiple dopamine receptors mediate the discriminative stimulus effects of dihydrexidine in rats
TLDR
Determinations of activity at second messenger systems revealed that DHX functioned as a full agonist at D3 receptors and a partial agonists at D2 receptors in vitro, suggesting that both D1 and D2/D3 receptors mediate the discriminative stimulus effects of DHX. Expand
Baseline Perfusion Alterations Due to Acute Application of Quetiapine and Pramipexole in Healthy Adults
TLDR
It is found that quetiapine reduced perfusion in the occipital and bilateral cerebellar cortex relative to placebo and pramipexole differentially modulate regional baseline cerebral blood flow. Expand
Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia
TLDR
Improved or novel new compounds, including D1 agonists with better pharmacokinetics, functionally selective D1 ligands, and D1R positive allosteric modulators are developed, including dihydrexidine, which at low doses improved working memory in monkeys. Expand
Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies
TLDR
The pharmacokinetics of ASP4345 suggest that single daily dosing is appropriate for ASP 4345, and the concentration of AS4345 in cerebrospinal fluid compared to free drug concentrations in plasma provides evidence of penetration ofAS4345 into the brain. Expand
The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
TLDR
PF-06412562 was tolerated in advPD patients and provides the feasibility for future safety and efficacy studies in this population with unmet needs. Expand
Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation
TLDR
PF-6142 improved performance in rodent models of NMDA receptor antagonist-induced cognitive dysfunction, and reversed ketamine-induced deficits in NHP performing the spatial delayed recognition task, and did not alter the efficacy of risperidone in assays predictive of antipsychotic-like effect in rodents including pre-pulse inhibition and conditioned avoidance responding. Expand
D1 receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats
TLDR
These data provide the first evidence that the reversal of the PCP-induced NOR deficit by D(1) agonism has an inverted U-shaped dose-response curve and that 5-HT(1A) and mGluR2/3 receptor signalling facilitates the efficacy of D( 1) agonists to improve these deficits. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia
TLDR
A single subcutaneous dose of dihydrexidine is tolerated and safe in patients with schizophrenia and does not produce delayed clinical or neuropsychological improvements. Expand
D1 Agonist Dihydrexidine Releases Acetylcholine and Improves Cognitive Performance in Rats
TLDR
The results of these studies suggest that the acetylcholine-releasing properties of dihydrexidine and other D1 agonists may underlie their cognition-enhancing activity and thus may have clinical value in the treatment of dementia. Expand
Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia
TLDR
Findings confirm that alteration of DLPFC D1 receptor transmission is involved in working memory deficits presented by patients with schizophrenia. Expand
Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys
TLDR
Monkeys exposed to low doses of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine develop difficulty in performing a previously learned delayed response (DR) task and the similarities between this primate model and the cognitive/behavioral deficits associated with early Parkinson's disease and attention deficit hyperactivity disorder suggest this may be a useful model for testing hypotheses concerning the pharmacological treatment of these disorders. Expand
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
TLDR
Although no differences were observed in the striatum relative to control subjects, binding of radioligand to D1R was reduced in the prefrontal cortex of schizophrenics, and this reduction was related to the severity of the negative symptoms and to poor performance in the Wisconsin Card Sorting Test. Expand
Dihydrexidine--the first full dopamine D1 receptor agonist.
TLDR
An updated overview of the pharmacology of dihydrexidine is provided and possible clinical utility of dopamine D(1) receptor agonists in various central nervous system disorders is discussed. Expand
Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys
TLDR
Results underscore the importance of DA D1 mechanisms in cognitive function, and provide functional evidence of DA system degeneration in aged monkeys, suggesting that excessive D1 stimulation may be deleterious to cognitive function. Expand
PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia.
TLDR
These results do not replicate previous postmortem and PET findings of altered central dopamine D(1) receptor binding in schizophrenia and the finding of a positive correlation between frontal D( 1) binding and scores on the negative symptom subscale of the BPRS is contrary to a previously reported finding ofA negative correlation. Expand
Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents.
TLDR
Interestingly, greater between-subject variation was found in the stimulation produced by SKF38393 in primate compared to rat brain, although the basis for this variation is unclear. Expand
An increase in [3H]SCH23390 binding in the cerebral cortex of postmortem brains of chronic schizophrenics
TLDR
The results suggest that there are changes in dopaminergic transmission through the D1 receptors in the parieto-temporal cortex of schizophrenia, and that the altered functions are involved in the pathophysiology of the disease. Expand
...
1
2
3
4
5
...